Jan 15 2014
Integrity Applications, Inc., developer of the GlucoTrack® model DF-F non-invasive blood glucose measurement device, has entered into a distribution agreement appointing Ultramedix Australasia Pty Ltd., with their depth of specialist clinical expertise and expertise in engineering, sales and marketing in the high-tech medical industry, as the exclusive distributor of the GlucoTrack device in Australia and New Zealand.
The appointment is subject to, and will take effect 14 days after, the approval of the listing of the GlucoTrack model DF-F device on the Australian Register of Therapeutic Goods (ARTG) register. According to the International Diabetes Federation, nearly 2 million diabetes patients live in Australia and New Zealand combined.
Saul Freedman, director of Ultramedix Australasia Pty Ltd, said, “We are looking forward to bringing the GlucoTrack model DF-F non-invasive blood glucose measurement device to diabetes patients in Australia and New Zealand. We believe Integrity Applications’ GlucoTrack represents a significant advance in future diabetes management.”
Based on the minimum purchase requirements contained in the distribution agreement, Ultramedix Australia is expected to purchase a minimum of $360,000 of GlucoTrack model DF-F devices from Integrity Applications in the first contract year. GlucoTrack will be made available to diabetes patients through the channels to be announced on Ultramedix Australia’s web site.
Avner Gal, President and CEO of Integrity Applications, said, “This distribution agreement marks an important milestone for our company and we look forward to providing patients with diabetes a new, non-invasive option for monitoring blood glucose. I am confident that the diabetes community in Australia and New Zealand, as well as other nations, will soon learn about the many benefits of GlucoTrack, and use this tool as a fresh alternative to existing blood glucose monitoring options.”
GlucoTrack features a small sensor that clips to the earlobe and measures the wearer’s blood glucose level by taking measurements using three technologies. The measurements are analyzed using a proprietary algorithm and displayed on a portable handheld device, the size of a mobile phone. The derived blood glucose measurement is also announced verbally, making it suitable for the elderly and vision-impaired diabetes patients. The company has obtained a CE Mark for its GlucoTrack Model DF-F in Europe and intends to seek Food and Drug Administration approval for GlucoTrack in the United States.
To watch a video detailing the benefits of GlucoTrack, please visit the following link: http://www.integrity-app.com/the-glucotrack/
About Integrity Applications, Inc.
Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack model DF-F non-invasive glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost and difficulty or discomfort of conventional (invasive) spot finger stick devices. Integrity Applications works primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd.